Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Astria Therapeutics, Inc.CATB · Entity 68888 | CMO; SVP Clinical Development | February 12, 2020 | February 14, 2020 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | CMO | August 12, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Astria Therapeutics, Inc.
Report date February 12, 2020 · Filed February 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.32 · Expires 2030-02-11 | Direct | 60,000 |
Reported balance
After 2020-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-12 · Grant · Acquired 60,000 · Balance 60,000 F1: This option was granted on February 12. 2020 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years at a rate of 2.0333% per month. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 12. 2020 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years at a rate of 2.0333% per month.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 65,000 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 65,000 · Balance 65,000 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,919 | $43.41 | $126,703.57 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 7 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,625 F7 · shares: The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F8 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · derivative · entry 11 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F12 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 32,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · derivative · entry 10 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2036-08-12 F11 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 7,031 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · derivative · entry 9 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,094 Underlying: Common Stock · 7,031 shares Expires 2035-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · derivative · entry 8 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,563 Underlying: Common Stock · 5,781 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 800 | $44.52 | $35,614.00 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 6 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,544 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F6 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.43 to $44.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 104 | $44.43 | $4,620.23 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 5 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,344 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.42 to $44.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,779 | $43.71 | $121,462.59 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 4 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,448 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,839 | $43.78 | $124,302.78 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,227 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.23 to $44.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 7,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:54 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 887 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:41 UTC Amendment | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001644087-26-000006 · primarydocument.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 05, 2026 Filed May 5, 2026 17:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001644087-26-000004 · primarydocument.xml · derivative · entry 4 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 50,000 shares Expires 2033-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 05, 2026 Filed May 5, 2026 17:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 50,000 | $38.57 | $1,928,400.00 |
DisclosureSEC source: 0001644087-26-000004 · primarydocument.xml · nonDerivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,367 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $39.96 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 5, 2026 17:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 50,000 | $7.08 | $354,000.00 |
DisclosureSEC source: 0001644087-26-000004 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 5, 2026 17:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 5,230 | $31.29 | $163,662.91 |
DisclosureSEC source: 0001644087-26-000004 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,367 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.72 to $31.66, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 17:01 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,662 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001644087-26-000003 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 28,662 shares Expires 2033-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 17:01 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 28,662 | $32.31 | $926,095.02 |
DisclosureSEC source: 0001644087-26-000003 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 17:01 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 28,662 | $7.08 | $202,926.96 |
DisclosureSEC source: 0001644087-26-000003 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 23:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,338 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001644087-26-000002 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,662 Underlying: Common Stock · 21,338 shares Expires 2033-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 23:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 21,338 | $32.12 | $685,308.28 |
DisclosureSEC source: 0001644087-26-000002 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 23:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 21,338 | $7.08 | $151,073.04 |
DisclosureSEC source: 0001644087-26-000002 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 21:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 6,735 | $30.98 | $208,635.48 |
DisclosureSEC source: 0001644087-26-000001 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,597 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 21:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 9,623 | $30.98 | $298,099.37 |
DisclosureSEC source: 0001644087-26-000001 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,332 F1 · shares: The shares sold were acquired through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2022 (1,392 shares), November 15, 2022 (1,406 shares), May 15, 2023 (1,451 shares), November 15, 2023 (1,751 shares), May 15, 2024 (1,803 shares), and November 15, 2024 (1,820 shares). F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 594 shares purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:41 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001562180-25-005794 · primarydocument.xml · derivative · entry 5 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2035-08-12 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:41 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 28,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005794 · primarydocument.xml · derivative · entry 4 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2035-08-12 F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:41 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005794 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,344 Underlying: Common Stock · 5,781 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:41 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,862 | $13.39 | $38,329.05 |
DisclosureSEC source: 0001562180-25-005794 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,361 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:41 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005794 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 854 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| May 02, 2025 Filed May 8, 2025 01:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 5,187 | $16.45 | $85,347.94 |
DisclosureSEC source: 0001562180-25-003657 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,588 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.84, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003657 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,417 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003657 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:05 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001562180-25-000697 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 25,000 shares Expires 2033-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:05 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 25,000 | $27.63 | $690,657.50 |
DisclosureSEC source: 0001562180-25-000697 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,358 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $27.09 to $27.96, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:05 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 25,000 | $7.08 | $177,000.00 |
DisclosureSEC source: 0001562180-25-000697 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. F2 · balance_after: Includes 1,820 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 7,162 | $28.29 | $202,602.95 |
DisclosureSEC source: 0001562180-24-006945 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,538 F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $28.28 to $28.29, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 1,803 shares purchased on May 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 23,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006257 · primarydocument.xml · derivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,125 Underlying: Common Stock · 23,125 shares Expires 2034-08-12 F2 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 138,750 | $0.00 Strike: $17.05 | $0.00 |
DisclosureSEC source: 0001562180-24-006257 · primarydocument.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,750 Underlying: Common Stock · 138,750 shares Expires 2034-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on August 12, 2024, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:27 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 3,682 | $18.91 | $69,626.62 |
DisclosureSEC source: 0001562180-24-003826 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,897 F2 · kind: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:27 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003826 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,417 Underlying: Common Stock · 10,417 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:27 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003826 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,451 shares purchased on May 15, 2023 and 1,751 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 23:13 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001562180-23-006452 · primarydocument.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2023 Filed May 3, 2023 22:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 3,254 | $8.90 | $28,976.54 |
DisclosureSEC source: 0001562180-23-003919 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,960 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 10,416 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003919 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,834 Underlying: Common Stock · 10,416 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 10,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003919 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,392 shares purchased on May 15, 2022 and 1,406 shares purchased on November 15, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 21:41 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001562180-22-006026 · primarydocument.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2032-08-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 31,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-003663 · primarydocument.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2025-05-01 F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $16.38 | $0.00 |
DisclosureSEC source: 0001562180-21-005461 · primarydocument.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| April 30, 2021 Filed May 4, 2021 20:34 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $28.64 | $0.00 |
DisclosureSEC source: 0001562180-21-003139 · primarydocument.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 13,964 shares Expires 2031-04-30 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will become vested and exercisable on April 26, 2022 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 15:00 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $5.32 | $0.00 |
DisclosureSEC source: 0001179110-20-001613 · edgar.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO; SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-11 F1 · derivative.exercise_date: This option was granted on February 12. 2020 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years at a rate of 2.0333% per month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.